

# XVIII International Congress «Antimicrobial Therapy»

Moscow, 25-27 May 2016

## Scientific programme

25 May, Wednesday

<b>Symposium: «Nosocomial pneumonia: new Russian clinical guidelines»</b>		
09.00-09.25	Microbiological diagnostics of nosocomial pneumonia: reasonable minimum and optimal maximum	M. Sukhorukova (Russia)
09.25-09.50	Treatment of patients with nosocomial pneumonia: what is important except antibiotics?	S. Avdeev (Russia)
09.50-10.15	Current options for control of extremely-resistant Gram(-) pathogens in nosocomial pneumonia	V. Belotserkovskiy (Russia)
10.15-10.40	Anti-MRSA drugs in nosocomial pneumonia: when and what?	V. Kulabukhov (Russia)
10.40-10.55	<i>Discussion</i>	

10.55-11.15 Coffee break

<b>Symposium: «Options for treatment of infections caused by Gram(-) pathogens in the era of increasing antimicrobial resistance»</b>		
11.15-11.40	Resistance in Gram(-) pathogens: current state and the future	R. Kozlov (Russia)
11.40-12.05	Profile of a patient with multi-resistant infection in urology. To treat or not to treat and how to choose the right therapeutic option?	T. Perepanova (Russia)
12.05-12.30	Profile of a patient with multi-resistant infection in surgical wards. What determines empiric antibacterial therapy?	A. Golub (Russia)
12.30-12.55	Profile of a patient with multi-resistant infection in ICU. Clinical cases.	V. Rudnov (Russia)
12.55-13.10	<i>Discussion</i>	

13.10-13.30 Coffee break

<b>Symposium: «New old problems and new antimicrobials of the old classes»</b>		
13.30-14.00	What is new in the 3 <sup>rd</sup> international sepsis consensus?	J. Cohen (UK)
14.00-14.25	Evolution of cephalosporins from the view of clinical pharmacologist	S. Ziryanov (Russia)
14.25-14.50	Cephalosporins: a view of infection diseases specialist	V. Beloborodov (Russia)
14.50-15.15	$\beta$ -lactams in severe community-acquired pneumonia – which is better?	A. Sinopalnikov (Russia)
15.15-15.25	<i>Discussion</i>	

15.25-15.45 Coffee break

<b>Plenary Session I</b>		
15.45-16.15	All about intravenous fosfomycin	O. Stetsiouk (Russia)
16.15-16.45	Dual carbapenem therapy – what's the point?	A. Dekhnich (Russia)
16.45-17.15	Perspectives of use of new $\beta$ -lactam/ $\beta$ -lactamase inhibitors combinations in Russia	M. Edelstein (Russia)
17.15-17.45	Polymyxin B and colistin: clinically significant similarities and differences	D. Szabo (Hungary)
17.45-18.00	<i>Discussion</i>	
18.00	<b>Opening of the Congress</b>	
18.30	<b>Welcome cocktail</b>	

## 26 May, Thursday

<b>Netherlands-Russian Symposium: «Controlling the antimicrobial resistance»</b>		
09.00-09.30	The need for bacteriological diagnostics: from societal and from individual patient point of view	T. Leenstra (Netherlands)
09.30-09.55	Surveillance of antimicrobial resistance in Russia: what we have now and what is needed to be done in the nearest future	R. Kozlov (Russia)
09.55-10.25	Optimizing infections prevention in clinical setting: the view from the Netherlands	J. van Dissel (Netherlands)
10.25-10.50	Optimizing infections prevention in clinical setting: the view from Russia	O. Ershova (Russia)
10.50-11.00	<i>Discussion</i>	

11.00-11.15 Coffee break

<b>Symposium: «Current clinical guidelines: an international review»</b>		
11.15-11.40	STD treatment guidelines: what's new?	M. Gomberg (Russia)
11.40-12.10	Therapy of infections of lower urinary tract: clinical guidelines and real practice	G. Cornaglia (Italy)
12.10-12.35	ESCMID guidelines for diagnostics and treatment of community-acquired meningitis	I. Karpov (Belarus)
12.35-13.05	Diagnostics and therapy of <i>Clostridium difficile</i> – associated diarrhoea	P. Hawkey (UK)
13.05-13.30	Review of current guidelines for treatment of patients with infectious endocarditis	D. Popov (Russia)
13.30-13.40	<i>Discussion</i>	

13.40-14.00 Coffee break

<b>Plenary Session II</b>		
14.00-14.25	What is dangerous in inadequate antibacterial therapy of complicated skin and soft tissue infections	N. Zubareva (Russia)
14.25-14.55	Study of intracellular activity of antibiotics: significance for the clinical practice	P. Tulkens (Belgium)
14.55-15.20	Probiotics: is there going to be a new effective class of drugs in the nearest future?	I. Andreeva (Russia)
15.20-15.45	New niches of surgical antimicrobial prophylaxis: focusing on ophthalmology	E. Eliseeva (Russia)
15.45-15.55	<i>Discussion</i>	

15.55-16.10 Coffee break

<b>Symposium: «Therapy and diagnostics of fungal infections»</b>		
16.10-16.35	Invasive candidiasis: do we have rapid diagnostic approaches?	G. Klyasova (Russia)
16.35-17.00	Intra-abdominal candidiasis: just a nosology or something more?	A. Veselov (Russia)
17.00-17.30	Prophylaxis of invasive candidiasis: how to stratify patients into risk groups?	F. Montravers (France)
17.30-17.55	Chronic pulmonary aspergillosis: ERS and ESCMID guidelines	N. Klimko (Russia)
17.55-18.10	<i>Discussion</i>	

**27 May, Friday**

<b>Plenary Session III</b>		
9.00-9.30	Efficacy of antimicrobial therapy in infectious endocarditis: results of Russian study	V. Tyurin (Russia)
9.30-10.00	Zika virus: how great is the threat?	V. Maleev (Russia)
10.00-10.30	Respiratory infection: what to do and who is responsible if there is no effect on antimicrobial therapy	D. Ruzanov (Belarus)
10.30-11.00	Aminoglycosides: horizons of clinical use	G. Reshedko (Russia)
11.00-11.15	<i>Discussion</i>	

11.15-11.30 Coffee break

<b>Enlarged Expert Meeting of Commission on Clinical Microbiology and Antimicrobial Resistance</b>		
11.30-12.00	Perspectives on accreditation of specialists in microbiology	N. Vasilyeva (Russia)
12.00-12.20	Antimicrobial resistance in <i>Chlamydia</i> and <i>Mycoplasma</i> : prevalence and diagnostic options. Discussion of relevance of development of clinical guidelines.	I. Edelstein (Russia)
12.20-12.40	WHO antimicrobial resistance surveillance program. Results of external quality assurance.	M. Sukhorukova (Russia)
12.40-13.00	Update on antimicrobial resistance in nosocomial pathogens in Russia	N. Ivanchik (Russia)
13.00-13.20	Approval of yearly report form for microbiological laboratories	I. Nizhegorodtseva (Russia)
13.20-13.40	Antibiotic resistance monitoring in North-Caucasian Federal District: current state and perspectives	E. Alieva (Russia)
13.40-14.00	Monitoring of antimicrobial resistance in <i>Neisseria gonorrhoeae</i> in Russia	D. Deryabin (Russia)
14.00-14.20	New perspectives of MALDI Biotyper in clinical microbiology	V. Kazakov (Russia)
14.20-14.50	A tool for complex operative monitoring of antibiotic resistance in Russia: a plan of development	R. Kozlov (Russia) A. Dekhnich (Russia) A. Kuzmenkov (Russia) B. Makushkin (Russia)
14.50-15.00	<i>Discussion</i>	
<i>Closing of the Congress</i>		